Rock  Soffer net worth and biography

Rock Soffer Biography and Net Worth

Director of Longeveron
Rock Soffer joined Longeveron’s Board of Directors in March 2020. Mr. Soffer is President, Special Project Division at Turnberry Associates, where he oversees leasing, asset acquisitions, zoning and site approvals, as well as the development of other specialty projects. He has experience in managing and securing financing for complex projects, as well as overseeing a number of developments in Florida, such as the redevelopment of an almost 200,000 square-foot open-air lifestyle shopping center in Aventura. In addition, Mr. Rock Soffer was tasked with overseeing the referendum for the new 800-key Miami Beach Convention Center luxury hotel. Upon completion, the privately-funded property will be the cornerstone of the Convention Center District in Miami Beach. Mr. Rock Soffer is an advocate for responsible, environmentally sustainable development. He is actively involved in his local community and sits on the boards of AYITI Community Trust, and the Institute of Contemporary Art Miami.

What is Rock Soffer's net worth?

The estimated net worth of Rock Soffer is at least $423,324.02 as of April 11th, 2024. Mr. Soffer owns 208,534 shares of Longeveron stock worth more than $423,324 as of November 2nd. This net worth estimate does not reflect any other investments that Mr. Soffer may own. Learn More about Rock Soffer's net worth.

How do I contact Rock Soffer?

The corporate mailing address for Mr. Soffer and other Longeveron executives is 1951 NW 7TH AVENUE SUITE 520, MIAMI FL, 33136. Longeveron can also be reached via phone at 305-302-7158 and via email at [email protected]. Learn More on Rock Soffer's contact information.

Has Rock Soffer been buying or selling shares of Longeveron?

Rock Soffer has not been actively trading shares of Longeveron during the last quarter. Most recently, on Thursday, April 11th, Rock Soffer bought 31,915 shares of Longeveron stock. The stock was acquired at an average cost of $2.35 per share, with a total value of $75,000.25. Following the completion of the transaction, the director now directly owns 208,534 shares of the company's stock, valued at $490,054.90. Learn More on Rock Soffer's trading history.

Who are Longeveron's active insiders?

Longeveron's insider roster includes James Clavijo (CFO), Geoff Green (CEO), Joshua Hare (Insider), Paul Lehr (General Counsel), and Rock Soffer (Director). Learn More on Longeveron's active insiders.

Are insiders buying or selling shares of Longeveron?

During the last year, Longeveron insiders bought shares 5 times. They purchased a total of 150,436 shares worth more than $370,049.60. The most recent insider tranaction occured on April, 11th when CEO Mohamed Wa'el Ahmed Hashad bought 10,638 shares worth more than $24,999.30. Insiders at Longeveron own 19.1% of the company. Learn More about insider trades at Longeveron.

Information on this page was last updated on 4/11/2024.

Rock Soffer Insider Trading History at Longeveron

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
4/11/2024Buy31,915$2.35$75,000.25208,534View SEC Filing Icon  
5/23/2022Sell800$77.80$62,240.0067,635View SEC Filing Icon  
5/20/2022Sell750$80.60$60,450.0068,435View SEC Filing Icon  
10/13/2021Buy1,200$37.60$45,120.00View SEC Filing Icon  
10/11/2021Buy390$34.50$13,455.00View SEC Filing Icon  
2/12/2021Buy10$80.50$805.00View SEC Filing Icon  
See Full Table

Rock Soffer Buying and Selling Activity at Longeveron

This chart shows Rock Soffer's buying and selling at Longeveron by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Longeveron Company Overview

Longeveron logo
Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States and Japan. The company's lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors. It is conducting Phase 1, Phase 1/2, Phase 2a, and Phase 2b clinical trials in various indications, such as aging-related frailty, alzheimer's disease, and hypoplastic left heart syndrome. Longeveron Inc. was incorporated in 2014 and is headquartered in Miami, Florida.
Read More

Today's Range

Now: $2.03
Low: $2.03
High: $2.12

50 Day Range

MA: $2.03
Low: $1.78
High: $2.41

2 Week Range

Now: $2.03
Low: $0.77
High: $23.90

Volume

379,146 shs

Average Volume

3,983,970 shs

Market Capitalization

$29.15 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.36